Semaglutide drugs—which mimic a hormone that regulates blood glucose levels and are used for diabetes and obesity—became a target of the pharmaceutical industry and have ultimately ended up being prescribed in clinics and dispensed by pharmacies as one of the most effective tools. However, the ease with which they are discontinued prematurely is beginning to worry endocrinologists. A study conducted in Denmark (where the pharmaceutical giant Novo Nordisk manufactures) warns that half of semaglutide users discontinue treatment within a year.